복막 투석 시장 : 제품 유형별, 치료 영역별, 용도별, 최종 사용자별 - 시장 예측(2026-2032년)

The Peritoneal Dialysis Market was valued at USD 9.98 billion in 2025 and is projected to grow to USD 10.39 billion in 2026, with a CAGR of 6.18%, reaching USD 15.20 billion by 2032.

Foundational overview of evolving care models, technology progress, and clinical priorities reshaping peritoneal dialysis delivery across clinical and home settings

Peritoneal dialysis remains a vital modality within renal replacement therapy, driven by changing patient demographics, care-delivery preferences, and continuous technological refinement. Over the past decade, clinicians and health systems have increasingly recognized the potential of peritoneal dialysis to support home-based care pathways, reduce inpatient exposure, and offer patient-centered autonomy. These shifts have been reinforced by innovations in cycler automation, improvements in solution biocompatibility, and integrated remote monitoring capabilities that together lower barriers to outpatient management.

Consequently, stakeholders from device manufacturers and solution formulators to dialysis providers and payers are reassessing clinical protocols, supply chains, and training models to align with evolving practice patterns. Clinicians emphasize preserving peritoneal membrane function and simplifying therapy regimens to improve adherence, while health systems focus on value-based outcomes and operational efficiencies. As a result, product roadmaps and strategic investments increasingly prioritize durability, connectivity, and ease of use. This introductory overview sets the foundation for a focused examination of drivers, constraints, and strategic levers that affect adoption and innovation within peritoneal dialysis moving forward.

How converging advances in automation, solution chemistry, remote monitoring, and policy incentives are redefining peritoneal dialysis care models and supply priorities

The landscape of peritoneal dialysis is undergoing transformative shifts driven by converging forces in technology, care delivery, and policy. On the technology front, automation has advanced from basic cycler functionality to intelligent systems that reduce manual steps and support adherence through scheduling, alerts, and remote data transmission. Meanwhile, solution chemistry has progressed toward formulations that reduce peritoneal membrane stress and lower complication risk, enabling longer-term therapy viability.

Simultaneously, the care-delivery paradigm is shifting toward decentralization: more patients are being managed at home with structured clinical oversight conducted remotely. This transition has catalyzed investment in telehealth-enabled monitoring, integrated supply logistics, and patient education platforms. Policy and reimbursement frameworks in several jurisdictions are adapting to incentivize home therapies, though heterogeneity remains across payers. Finally, supply chain resilience and supplier diversification have become strategic priorities after recent disruptions, prompting manufacturers to reassess sourcing, contract terms, and nearshoring options. Together, these shifts create both opportunities for differentiation and new operational challenges for manufacturers, providers, and health systems.

Assessment of evolving procurement dynamics and manufacturer strategies in response to 2025 tariff shifts that influence cost, sourcing, and service continuity

The introduction of new tariff measures in 2025 has injected additional complexity into procurement and supply chain planning for peritoneal dialysis stakeholders. Increased duties on imported consumables and capital equipment have pressured cost structures for providers and manufacturers that rely on global sourcing of bags, connectors, and cycler components. In response, some suppliers have accelerated diversification of manufacturing footprints, prioritized local sourcing of critical raw materials, and revisited supplier consolidation strategies to mitigate exposure to trade policy volatility.

These developments have also prompted health systems and purchasing groups to renegotiate long-term supply agreements, incorporate tariff contingency clauses into contracts, and evaluate total landed cost rather than unit price alone. At the same time, accelerated interest in domestic manufacturing capacities and strategic stockpiling has emerged as a buffer against future tariff-driven disruptions. Regulatory agencies and payers are increasingly attentive to how cost pressures may affect access and utilization patterns, fueling dialogue on reimbursement adjustments and value-based contracting. The net effect is a more complex procurement environment where operational agility, scenario planning, and supplier ecosystem resilience are essential to maintain continuity of peritoneal dialysis services.

Deep-dive segmentation insights connecting product portfolios, therapeutic indications, clinical applications, and end-user requirements to strategic priorities

Insights drawn from product, therapeutic, application, and end-user segmentation reveal differentiated opportunities and constraints across the peritoneal dialysis ecosystem. By product type, the space encompasses accessories-for example, bags for peritoneal dialysis solutions, drainage bags, peritoneal dialysis catheter kits, and transfer sets-alongside PD machines such as automated peritoneal dialysis cyclers and continuous ambulatory peritoneal dialysis devices, and a range of peritoneal solutions including biocompatible solutions, glucose-based solutions, and low-glucose solutions. These product distinctions directly affect procurement cycles, clinical training needs, and capital investment decisions, with consumables driving recurring logistics priorities and capital devices influencing clinical workflow redesign.

By therapeutic area, the therapy serves acute kidney injury, chronic kidney disease, and congestive heart failure populations, each with unique clinical trajectories and utilization patterns that inform device selection and solution choice. From an application perspective, managing etiologies such as diabetic nephropathy, glomerulonephritis, lupus nephritis, and polycystic kidney disease requires tailored clinical protocols and distinct monitoring strategies. End users vary from dialysis centers to home healthcare programs and hospitals, and each setting imposes different requirements for staff training, inventory management, and remote support. Integrating these segmentation lenses provides a granular view for prioritizing R&D, commercial channels, and clinical evidence generation.

Comparative view of how regional payer frameworks, clinical practice variation, and manufacturing footprints shape adoption and access across global peritoneal dialysis markets

Regional dynamics materially shape technology adoption, regulatory pathways, and care-delivery models across the peritoneal dialysis landscape. In the Americas, clinicians and providers are balancing strong clinical interest in home-based therapies with payer-driven imperatives for demonstrable outcomes and cost containment, creating fertile ground for value propositions that combine improved patient experience with measurable reductions in hospital utilization. Regulatory clarity and established reimbursement mechanisms in certain markets accelerate adoption, but disparities exist across subnational payers.

Across Europe, the Middle East & Africa, the landscape is heterogeneous: Western European markets demonstrate advanced clinical protocols and growing telehealth integration, while other territories contend with infrastructure constraints and variable access to consumables. Policymakers and health systems in the region increasingly prioritize supply chain resilience and equitable access, prompting innovative public-private partnerships. In the Asia-Pacific region, rapid growth in chronic kidney disease prevalence is intersecting with expanding healthcare infrastructure, rising demand for home therapy solutions, and active adoption of local manufacturing strategies. Diverse reimbursement regimes and workforce considerations underscore the need for region-specific commercialization and implementation plans.

Competitive dynamics in peritoneal dialysis are characterized by a mix of specialized device manufacturers, solution formulators, contract manufacturers, and emerging digital health entrants. Leading product developers continue to invest in cycler automation, sensor integration, and patient-facing applications that enable remote monitoring and adherence support. At the same time, solution innovators are focused on improving biocompatibility and reducing metabolic burden to preserve peritoneal membrane function and extend therapy longevity.

Strategic partnerships, distribution alliances, and selective acquisitions are common as established players seek to broaden portfolios and newcomers aim to scale more rapidly. Contract manufacturing and outsourcing have become important levers to manage cost and accelerate time to market, particularly where tariff dynamics or raw material constraints affect production economics. Service and support models are also evolving: companies that integrate clinical training, supply logistics, and digital follow-up can differentiate around total cost of care and patient outcomes. Finally, private equity and corporate investors remain active in the space, drawn to predictable recurring revenue from consumables and the growing clinical emphasis on home-based therapies.

Actionable strategic moves for manufacturers, providers, and purchasers to advance resilience, clinical value, and adoption of home-focused peritoneal dialysis solutions

Industry leaders seeking to navigate the complex peritoneal dialysis environment should adopt a multi-dimensional strategy that aligns product innovation with operational resilience and payer engagement. First, prioritize product development that reduces clinician burden and enhances patient usability, including cycler automation, simplified connection systems, and solutions engineered for membrane preservation. Simultaneously, strengthen supply chain resilience by diversifying supplier bases, considering nearshoring for critical components, and embedding tariff contingencies into procurement contracts to reduce exposure to policy shifts.

Equally important is to build robust clinical evidence demonstrating outcomes and cost-effectiveness tailored to key therapeutic segments and applications. Invest in pilot programs that combine remote monitoring, clinician support, and patient education to validate real-world benefits and support reimbursement discussions. Forge partnerships with payers and health systems to pilot value-based contracting models that align incentives around reduced hospitalization and enhanced quality of life. Finally, enhance commercial capabilities by developing specialized channels for home healthcare providers and by training clinical teams to support decentralized care pathways. These combined actions will position organizations to capture long-term value while protecting margins amid ongoing policy and supply-chain uncertainty.

Robust mixed-methods approach combining practitioner interviews, policy analysis, and data triangulation to deliver validated and actionable peritoneal dialysis insights

The research underpinning these insights integrates primary qualitative interviews, secondary literature synthesis, and comparative policy analysis to ensure robust, triangulated findings. Primary inputs include structured discussions with nephrologists, dialysis nurses, procurement officers, device engineers, and payer representatives to capture clinical workflows, procurement imperatives, and reimbursement considerations. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, technical product specifications, and public policy statements, which together contextualize clinical and commercial trends.

Data synthesis employed cross-validation techniques to reconcile divergent perspectives and identify consistent patterns in technology adoption, supply chain strategies, and regional policy responses. Scenario mapping was used to explore potential outcomes of tariff shifts and reimbursement changes, while sensitivity analyses tested the resilience of strategic recommendations under different operational constraints. Quality assurance included peer review by clinical and commercial experts to confirm factual accuracy and relevance. This mixed-methods approach ensures that conclusions are grounded in practitioner experience and validated against objective documentary evidence.

Concise synthesis of strategic imperatives and stakeholder alignments required to scale clinically effective and operationally resilient peritoneal dialysis programs

In summary, peritoneal dialysis stands at an inflection point where technology, policy, and care-delivery preferences intersect to create both significant opportunities and operational challenges. Advances in automation and solution biocompatibility are making home-based therapy more feasible and clinically attractive, yet trade policy shifts and supply chain vulnerabilities necessitate proactive mitigation strategies. Stakeholders that align product development with service models, invest in clinical evidence, and adopt resilient sourcing practices will be best positioned to meet growing clinical demand while protecting margins.

As the clinical community continues to emphasize patient-centered, outpatient care models, the ability to demonstrate improved outcomes, cost-effectiveness, and operational reliability will determine which solutions gain broad adoption. Therefore, collaboration across manufacturers, providers, payers, and regulators is essential to enable scalable, accessible, and sustainable peritoneal dialysis programs. The conclusion reinforces the imperative for strategic agility, clinical rigor, and stakeholder alignment as the sector advances into the next phase of care transformation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peritoneal Dialysis Market, by Product Type

• 8.1. Accessories
  • 8.1.1. Bags for PD solutions
  • 8.1.2. Drainage bags
  • 8.1.3. Peritoneal Dialysis Catheter Kit
  • 8.1.4. Transfer sets
• 8.2. PD Machines
  • 8.2.1. Automated Peritoneal Dialysis Cycler
  • 8.2.2. Continuous Ambulatory Peritoneal Dialysis
• 8.3. Peritoneal Solution
  • 8.3.1. Biocompatible solutions
  • 8.3.2. Glucose-based solutions
  • 8.3.3. Low-glucose solutions

9. Peritoneal Dialysis Market, by Therapeutic Area

• 9.1. Acute Kidney Injury
• 9.2. Chronic Kidney Disease
• 9.3. Congestive Heart Failure

10. Peritoneal Dialysis Market, by Application

• 10.1. Diabetic Nephropathy
• 10.2. Glomerulonephritis
• 10.3. Lupus Nephritis
• 10.4. Polycystic Kidney Disease

11. Peritoneal Dialysis Market, by End User

• 11.1. Dialysis Centers
• 11.2. Home Healthcare
• 11.3. Hospitals

12. Peritoneal Dialysis Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Peritoneal Dialysis Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Peritoneal Dialysis Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Peritoneal Dialysis Market

16. China Peritoneal Dialysis Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Advin Health Care
• 17.6. Angiplast Pvt. Ltd.
• 17.7. B. Braun Medical Ltd
• 17.8. Baxter International, Inc.
• 17.9. Becton, Dickinson and Company
• 17.10. Cook Group Incorporated
• 17.11. Diaverum AB by M42
• 17.12. Fresenius Medical Care AG
• 17.13. Huaren Pharmaceutical Co., Ltd.
• 17.14. JDmeditech
• 17.15. JMS Co., Ltd.
• 17.16. Medionics International Inc.
• 17.17. Mitra Industries
• 17.18. Mozarc Medical
• 17.19. Opterion Health AG
• 17.20. PFM Medical, Inc.
• 17.21. Renax Biomedical Technology Co., Ltd.
• 17.22. Renfrew Group International
• 17.23. Romsons Prime Private limited
• 17.24. Terumo Corporation
• 17.25. Toray Industries, Inc.
• 17.26. Vivance